Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Sep 30, 2025
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-25-277466General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-419.92% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-35.58% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-353.42% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
221.22% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
71.34% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesHistory building
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 0.91%
- Current
- 0.00%
- Delta
- -0.91%
- Previous
- -115.61%
- Current
- -419.92%
- Delta
- -304.31%
- Previous
- 11.14%
- Current
- -35.58%
- Delta
- -46.72%
- Previous
- -292.32%
- Current
- -353.42%
- Delta
- -61.10%
- Previous
- 267.77%
- Current
- 221.22%
- Delta
- -46.55%
- Previous
- 42.76%
- Current
- 71.34%
- Delta
- 28.58%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_DECREASED →Transitioned To · CUE CASH_GENERATION_DECREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_DECREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.